Two Immunoassays Compared for Determination of Serum Vitamin D
By LabMedica International staff writers Posted on 06 Jul 2021 |

Image: The IDS-iSYS Multi-Discipline Automated System Analyzer (Photo courtesy of Immunodiagnostic Systems)
Vitamin D is a fat-soluble steroid prohormone that is generated mainly in the skin by photochemical conversion of 7-dehydrocholesterol. 25-hydroxyvitamin D (25(OH)D) is its main storage form and is present in blood at very high concentration with respect to the active form 1,25-dihydroxyvitamin D.
The difficulties in the determination of 25(OH)D are related to its fat soluble nature, as well as its strong binding to the vitamin D binding protein (VDBP) and to serum albumin. On the other hand, although it would be appropriate for the different immunoassays to detect vitamin D2 and D3 in equimolar form, this is not usually fulfilled.
Clinical Biochemists at the Hospital Universitario Miguel Servet (Zaragoza, Spain) carried out a transversal descriptive observational study on a total of 184 individuals. The median age of the total of patients was 61 years old, with a minimum of 1 year and a maximum of 92. There were 31.5% men and 68.5% women. The samples came from both healthy patients and patients with various pathologies as bone, kidney, thyroid, cardiovascular, immune, neurological diseases and cancer.
The concentration of 25(OH)D was measured, as routine health analysis, by the automated IDS-iSYS 25VitD assay in an IDS-iSYS Multi-Discipline Automated System Analyzer (Vitro, Immunodiagnostic Systems Holdings PLC, Boldon Colliery, UK), which uses a chemiluminescence technology, which is fully automated. The same samples were processed by the Alinity i 25-OH Vitamin D assay in an Alinity i automated Analyzer (Abbott, Abbott Park, IL, USA), which is a one-step delayed-action immunoassay using chemiluminescent microparticles immunoassay (CMIA) technology.
The scientists reported that of the total patients, 52.7% received vitamin D supplements. The correlation coefficient of agreement for general group, supplementation group and group without supplementation was 0.92, 0.91 and 0.89, respectively. In all of them, a kappa index>0.75 was obtained. The mean value of the bias was higher for the supplemented group (−20.4 nmol/L) than for the group without treatment (−4.9 nmol/L). Graphically, a greater concordance between both assays was observed when patients receiving vitamin D supplements were excluded. The team observed lower concentrations of 25(OH)D in the IDS-iSYS 25 VitD assay when compared to the results obtained with the Alinity i 25-OH Vitamin D assay.
The authors concluded that the assays evaluated were not comparable to each other. Despite this, they show an excellent concordance in the evaluation of the vitamin D status. The study was published on June 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
Hospital Universitario Miguel Servet
Immunodiagnostic Systems Holdings PLC
Abbott
The difficulties in the determination of 25(OH)D are related to its fat soluble nature, as well as its strong binding to the vitamin D binding protein (VDBP) and to serum albumin. On the other hand, although it would be appropriate for the different immunoassays to detect vitamin D2 and D3 in equimolar form, this is not usually fulfilled.
Clinical Biochemists at the Hospital Universitario Miguel Servet (Zaragoza, Spain) carried out a transversal descriptive observational study on a total of 184 individuals. The median age of the total of patients was 61 years old, with a minimum of 1 year and a maximum of 92. There were 31.5% men and 68.5% women. The samples came from both healthy patients and patients with various pathologies as bone, kidney, thyroid, cardiovascular, immune, neurological diseases and cancer.
The concentration of 25(OH)D was measured, as routine health analysis, by the automated IDS-iSYS 25VitD assay in an IDS-iSYS Multi-Discipline Automated System Analyzer (Vitro, Immunodiagnostic Systems Holdings PLC, Boldon Colliery, UK), which uses a chemiluminescence technology, which is fully automated. The same samples were processed by the Alinity i 25-OH Vitamin D assay in an Alinity i automated Analyzer (Abbott, Abbott Park, IL, USA), which is a one-step delayed-action immunoassay using chemiluminescent microparticles immunoassay (CMIA) technology.
The scientists reported that of the total patients, 52.7% received vitamin D supplements. The correlation coefficient of agreement for general group, supplementation group and group without supplementation was 0.92, 0.91 and 0.89, respectively. In all of them, a kappa index>0.75 was obtained. The mean value of the bias was higher for the supplemented group (−20.4 nmol/L) than for the group without treatment (−4.9 nmol/L). Graphically, a greater concordance between both assays was observed when patients receiving vitamin D supplements were excluded. The team observed lower concentrations of 25(OH)D in the IDS-iSYS 25 VitD assay when compared to the results obtained with the Alinity i 25-OH Vitamin D assay.
The authors concluded that the assays evaluated were not comparable to each other. Despite this, they show an excellent concordance in the evaluation of the vitamin D status. The study was published on June 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
Hospital Universitario Miguel Servet
Immunodiagnostic Systems Holdings PLC
Abbott
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Molecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more